《新股表現》宏光(08646.HK)開報0.95元 高上市價逾23%
中國宏光(08646.HK)暗盤最多升28.6%高見0.99元遇壓,曾回順至0.85元,收0.87元,高上市價13%;該股首掛開報0.95元,較上市價0.77元,高逾23%,市前成交827萬股。
宏光於華南從事生產及銷售建築玻璃產品。是次上市共發售7,500萬股,其中10%公開發售獲近27倍超購,而國際配售認購不足部分已重新分配至公開發售,令其佔比增至20%,認購一手中籤率僅10.5%;股份以招股範圍(0.77-0.89元)下限定價,料集資淨額1,920萬元,主要用作升級現有生產設施、提升研發能力、加強信息技術、生產安全和環保基建設施,以及還債等。上市獨家保薦人東興證券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.